NCT07026799Active, not recruiting
Feasibility, Safety and Effectivity of an Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients During Induction Therapy
Investigation of an Exercise Intervention for Multiple Myeloma Patients With Stable and Unstable Osteolytic Lesions During Induction Therapy.
Source: ClinicalTrials.gov · Last updated 18 Jun 2025
Brief summary (registry, in English)
Physical exercise is an important supportive therapy for cancer patients, which improves quality of life and can effectively counteract the side effects of drug therapy. There is very little experience whether physical activity can also be performed safely by patients with malignant diseases that affect bone stability. This applies in particular to patients with multiple myeloma, a disease characterized by a monoclonal proliferation of plasma cells in the bone marrow and often accompanied by severe bony destruction. Aim of this exploratory randomized controlled trial is to evaluate feasibility, safety and effectivity of an orthopaedic-guided exercise intervention during induction therapy in newly diagnosed multiple myeloma patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 10 Jun 2025
- Start date
- 14 Apr 2023
- Primary completion date
- 27 Jun 2026
- Lead sponsor
- University Hospital Heidelberg
- Diseases
- Multiple myeloma
- NCT number
- NCT07026799
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 14 Apr 2023 to the primary completion date, 27 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- physical or mental limitation that would prevent participation in the training program or the planned follow-up visits.
- Carrying out a regular, intensive training program (min. 1h, 2x/week)
Who the study is looking for
- newly diagnosed multiple myeloma
- Survival prognosis \> 6 months
- ECOG status ≤ 3
- Age ≥18 years
- Patients who state that they want to carry out the training program at least 2 x/week and participate in the planned follow-up visits
- Ability to give informed consent
- Written consent to participate in the study
- Sufficient knowledge of written and spoken German
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heidelberg University Hospital - GMMG Study Group Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.